EGFR tyrosine kinase inhibitor, gefitinib [14, 15], or an anti-EGFR monoclonal antibody, cetuximab [13], cannot inhibit the thyroid hormone-induced stimulatory effect of ERK1/2 activation and EGFR expression in KRAS mutant CRC. Here, MAPK3 is linked to colorectal carcinoma.